These words uttered in 1901 relate directly to studies of thrombolytics for AMI. In GISSI-1 and 2 other major thrombolysis trials, the investigators did not require an informed consent of the ...

Although the benefits of thrombolytic therapy are well established in patients younger than age 75 years with acute ST-elevation myocardial infarction, the value of thrombolytic treatment in ...

Biogen has licensed a new drug from Japanese biotech TMS that it hopes could provide a big advance on an old treatment approach – using clot-busting thrombolytic drugs to treat ischaemic stroke.